Skip to main content
Boston Scientific seeks growth in minimally invasive aortic valves

Boston Scientific intends to file an application with the FDA for approval of its Lotus valve system by year's end, one of two heart valves it hopes to get to the market in an effort to bring in over $1 billion in revenue. The company, which saw a 6% net sales increase driven by growth in its medical surgical supplies in the quarter ending June 30, also plans to launch a US trial of the ACURATE neo AS valve system.

Full Story: